装甲 CAR-T 细胞抗耗竭：胶质母细胞瘤的工程化策略

Armoring CAR-T Cells Against Exhaustion: Engineering Strategies for Glioblastoma.

体内 CAR 免疫细胞工程：在恶性胶质瘤中的未来应用与挑战

In Vivo CAR-Based Immune Cell Engineering: Future Applications and Challenges in Malignant Glioma.

推进靶向蛋白降解：pLIRTAC 在胶质瘤与 CAR-T 细胞治疗中的作用

Advancing targeted protein degradation: pLIRTAC's role in glioma and CAR-T cell therapy.

异体 CAR-T 的制备可规避胶质母细胞瘤患者自体产品的功能缺陷

Generation of Allogeneic CAR-T Circumvents Functional Deficits in Patient-Derived Autologous Product for Glioblastoma.

非病毒型细胞因子诱导型含 SH2 蛋白位点特异性整合的成纤维细胞活化蛋白 α 靶向 CAR-T 细胞在胶质母细胞瘤中实现强效抗肿瘤疗效

Non-Viral Cytokine-Inducible SH2 Containing Protein Locus-Specific Integrated Fibroblast Activation Protein Alpha-Targeting Chimeric Antigen Receptor

胶质母细胞瘤的 CAR-T 细胞治疗：克服当前障碍与提升疗效的策略及其治疗意义

Chimeric antigen receptor T cell therapy for glioblastoma: overcoming current barriers and strategies to enhance efficacy for therapeutic implications

鞘内注射 CRISPR 编辑的同种异体 IL-13Rα2 CAR-T 细胞治疗复发高级别胶质瘤：临床前表征与 I 期试验

Intrathecal CRISPR-edited allogeneic IL-13Rα2 CAR T Cells for recurrent high-grade Glioma: preclinical characterization and phase I trial.

推进实体瘤中的 CAR-T 细胞治疗：现状与未来方向

Advancing CAR T-Cell Therapy in Solid Tumors: Current Landscape and Future Directions.

随着临床经验的积累和技术的持续创新，CAR-T 细胞疗法正稳步从实验性策略转变为实体瘤中的治疗现实，有望重塑癌症免疫治疗的未来。

从实验台到临床：实体恶性肿瘤 CAR-T 细胞治疗的新兴范式

From Bench to Bedside: Emerging Paradigms in CAR-T Cell Therapy for Solid Malignancies.

神经免疫学驱动的胶质瘤 CAR-T 细胞治疗：转化挑战与临床试验范式创新

Neuroimmunology-driven CAR T-cell therapeutics for gliomas: translational challenges and clinical trial paradigm innovation.